Renal Outcomes in Diabetes: SGLT2 Inhibitors and GLP-1 Agonists

Renal Outcomes in Diabetes: SGLT2 Inhibitors and GLP-1 Agonists

The goal of this activity is to improve renal outcomes in diabetic patients. After hearing and assimilating this program, the clinician will be better able to:
1. Recognize the renal benefits of using sodium-glucose transport protein 2 inhibitors and glucagon-like peptide 1 receptor agonists in diabetic patients with chronic kidney disease.

  • Provider:Lippincott Continuing Medical Education Institute, Inc.
  • Activity Link: https://www.audio-digest.org/Specialties/Internal-Medicine
  • Start Date: 2022-03-01 06:00:00
  • End Date: 2022-03-01 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
  • MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: Yes
  • Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Endocrinology, Diabetes, and Metabolism
«
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.